Brand to Generic Drug Leaders
Brand to Generic Drug Leaders Our generic drug company clients come to us because we help them grow their business. Patents and other FDA regulatory obstacles exist, but we help our clients overcome these legal obstacles. By employing keen business and legal sense, we help our clients win the race to the market. We do this by exercising great business judgment on legal strategy and when necessary, in Paragraph IV- Hatch Waxman litigation. Amin Talati Upadhye’s Brand to Generic Drug Practice provides strategic advice both to generic companies seeking to challenge patents and overcome FDA hurdles to bring drugs to market, and to Fortune 500 pharmaceutical companies seeking to strategically create patent and FDA barriers to protect their brand name products for the long term. Amin Talati Upadhye has developed a special renown in the representation of generic drug companies in Paragraph IV litigation: the process whereby generic companies challenge patents held by brand name companies in order to bring these important, often life-saving, medications to the market in generic forms. We know this space very well because we live it each day. We know what strategies will work and which won’t. We partner with our clients to provide excellent value-added legal advice that drives their business forward. We are never afraid to litigate, but we also know the value of a strategic settlement. Our client’s business needs come first. This is why clients call upon us.